A luminescent crystal smaller than a grain of dust could flag the earliest signs of Alzheimer’s disease from a single drop of blood. Alzheimer’s affects tens of millions of people worldwide, but current diagnostic tools catch it only after significant brain damage has already occurred. This project builds a biosensing platform called LUMOS-AD, using lanthanide-based metal-organic frameworks—nanoscale crystals that glow for unusually long periods when hit with light. The researchers will engineer these crystals to bind specifically to early-stage Alzheimer’s biomarkers in cerebrospinal fluid and blood. Because the crystals’ luminescence lasts far longer than background signals, the platform can detect vanishingly small concentrations of those biomarkers with high accuracy. If the platform works in clinical samples, it could make early Alzheimer’s diagnosis quantitative, widely accessible, and routine. That would shift treatment from managing late-stage symptoms to intervening when therapies have the best chance of slowing or halting the disease. The same sensing approach might eventually be adapted to detect other neurodegenerative conditions, though that is not part of this project. For now, the work is squarely focused on proving that these luminescent crystals can reliably spot Alzheimer’s before symptoms appear.
View original technical description
Alzheimer's disease (AD) is a devastating neurodegenerative disorder affecting tens of millions worldwide. As we are in the nascent stages of devising diagnostic and therapeutic tools for AD, there is a critical need for early detection techniques. To this end, we are proposing to develop a biosensing platform (LUMOS-AD) based on the use of lanthanide-based luminescent nano-metal (LUMOS) organic frameworks (MOFs) for the targeted recognition of early-stage AD biomarkers. LUMOS-AD taps into the unique optical properties of lanthanide ions. These luminescent MOFs, characterized by expansive surface areas and adjustable porosities, act as nanoscale probes. Suitably functionalized, they can identify AD biomarkers in cerebrospinal fluid and blood, and the inclusion of lanthanide ions in MOFs enhances their photostability, yielding prolonged luminescence lifetimes, thereby amplifying the signal-to- noise ratio in detection. Our project revolves around three main objectives: 1. MOF Design and Synthesis: Here, LUMOS-AD will generate luminescent MOFs, refining their structure for effective biomarker adsorption. Techniques like X-ray crystallography and photoluminescence spectroscopy will verify MOF functionality. 2. Biosensing Platform Development: We will build a robust platform using luminescent MOFs as the key detection elements. Surface treatments will attach specific antibodies to MOFs, enhancing their selectivity. 3. Early-stage AD Biomarker Detection: We will assess the capability of our platform to precisely identify AD biomarkers in clinical samples, with evaluations of its sensitivity and selectivity. Implementing LUMOS-AD promises to greatly facilitate quantitative and widely accessible AD diagnostics, potentially pioneering early detection and opening avenues for more tailored treatments, advancing our battle against AD.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know